Mei Han

ORCID: 0000-0001-9036-8359
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Plant Ecology and Soil Science
  • Drug Transport and Resistance Mechanisms
  • Lipid metabolism and disorders
  • Cancer Treatment and Pharmacology
  • Pharmacological Effects of Natural Compounds
  • Mast cells and histamine
  • Natural product bioactivities and synthesis
  • Chronic Myeloid Leukemia Treatments
  • Phytochemical compounds biological activities
  • Central Venous Catheters and Hemodialysis
  • Dialysis and Renal Disease Management
  • Hemodynamic Monitoring and Therapy
  • Gastrointestinal Tumor Research and Treatment
  • Neurological Disease Mechanisms and Treatments
  • Medicinal Plant Pharmacodynamics Research
  • Pharmacogenetics and Drug Metabolism
  • Fungal Biology and Applications

Sichuan University
2019

West China Hospital of Sichuan University
2019

Pfizer (China)
2018

Chinese Academy of Medical Sciences & Peking Union Medical College
2011

Melanomas harbor aberrations in the c-Kit gene. We tested efficiency of tyrosine kinase inhibitor imatinib selected patients with metastatic melanoma harboring mutations or amplifications.Forty-three were enrolled on this phase II trial. Each patient received a continuous dose 400 mg/d unless intolerable toxicities disease progression occurred. Fifteen who experienced allowed to escalate 800 mg/d.Forty-three eligible for evaluation, and median follow-up time was 12.0 months. The...

10.1200/jco.2010.33.9275 article EN Journal of Clinical Oncology 2011-06-21
Coming Soon ...